DUSP1 as a therapeutic target in fibroproliferative acute lung injury

DUSP1作为纤维增殖性急性肺损伤的治疗靶点

基本信息

  • 批准号:
    9066180
  • 负责人:
  • 金额:
    $ 39.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-01 至 2018-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are serious conditions with an unacceptably high overall mortality rate of ~25%. In addition, some patients develop a debilitating, persistent and sometimes fatal, fibrotic lung disease called fibroproliferative ALI. Unfortunately, there are no effective therapeutic approaches to prevent or treat this disorder. This project seeks to address this therapeutic need by investigating the role of dual specificity protein phosphatase-1 (DUSP1, aka MKP-1), a protein threonine/tyrosine phosphatase that dephosphorylates and inactivates the mitogen-activated protein kinases, p38 and JNK. In preliminary studies using mouse models of acute lung injury and fibrosis, we have shown that the development of lung fibrosis is ablated in mice lacking DUSP1. Our preliminary studies also show that genetic DUSP1 deficiency in mice impairs the ability of macrophages to undergo "alternative" programming leading to impaired production of pro-fibrotic growth factors including TGF-¿. These and other considerations have led us to hypothesize that DUSP1 is a therapeutic target that, when blocked, will reduce or prevent alternative macrophage programming, pro-fibrotic growth factor production and the development of ALI/ARDS-associated parenchymal lung fibrosis. These hypotheses will be addressed with three specific aims. Using genetic and conditional manipulation of DUSP1 expression in mouse models, the goal of Specific Aim 1 is to address the hypothesis that DUSP1 expression by macrophages is required for the development of fibroproliferative ALI. In Specific Aim 2, we will test the hypothesis that DUSP1-dependent fibrotic lung disease is mediated by alternatively programmed macrophages producing pro-fibrotic growth factors. Lastly, in Specific Aim 3, we will begin translating this work into humans by conducting pre-clinical studies in which we will assess two currently available small molecule DUSP1 expression inhibitors, currently approved for use in humans, for their ability to phenocopy DUSP1 deficiency and inhibit the development of parenchymal lung fibrosis in mice. Our proposed studies represent the first time that protein phosphatases have been investigated as therapeutic targets for the treatment of fibroproliferative ALI. Thus, a long-term goal of this proposal is to translate our anticipated findings into a clinical trial of DUSP1 inhibitors in ALI nd ARDS patients who are at risk for developing fibrotic lung disease. In addition, DUSP1 may also be a valid therapeutic target in other fibrotic lung disease, e.g. progressive pulmonary fibrosis.
描述(由申请人提供):急性肺损伤(ALI)及其更严重的形式急性呼吸窘迫综合征(ARDS)是严重的疾病,总死亡率高达约25%。此外,一些患者会出现一种使人衰弱、持续甚至致命的纤维化肺病,称为纤维增生性ALI。不幸的是,没有有效的治疗方法来预防或治疗这种疾病。该项目旨在通过研究双特异性蛋白磷酸酶-1(DUSP 1,又名MKP-1)的作用来解决这种治疗需求,DUSP 1是一种蛋白质苏氨酸/酪氨酸磷酸酶,可使促分裂原活化蛋白激酶p38和JNK去磷酸化和失活。在使用急性肺损伤和纤维化小鼠模型的初步研究中,我们已经表明,在缺乏DUSP 1的小鼠中,肺纤维化的发展被消融。我们的初步研究还表明,小鼠的遗传DUSP 1缺陷会损害巨噬细胞进行“替代”编程的能力,导致包括TGF-β在内的促纤维化生长因子的产生受损。这些和其他考虑使我们假设DUSP 1是一个治疗靶点,当被阻断时,将减少或阻止替代的巨噬细胞编程,促纤维化生长因子的产生和ALI/ARDS相关的实质性肺纤维化的发展。这些假设将与三个具体目标进行讨论。在小鼠模型中使用DUSP 1表达的遗传和条件操作,特定目标1的目标是解决巨噬细胞表达DUSP 1是纤维增生性ALI发展所需的假设。在具体目标2中,我们将检验DUSP 1依赖性纤维化肺病由产生促纤维化生长因子的交替编程巨噬细胞介导的假设。最后,在具体目标3中,我们将开始将这项工作转化为人类 通过进行临床前研究,我们将评估目前批准用于人类的两种目前可用的小分子DUSP 1表达抑制剂在小鼠中复制DUSP 1缺陷和抑制实质肺纤维化发展的能力。我们提出的研究代表了蛋白磷酸酶首次被研究作为治疗纤维增生性ALI的治疗靶点。因此,该提案的长期目标是将我们预期的发现转化为DUSP 1抑制剂在有发生纤维化肺病风险的ALI和ARDS患者中的临床试验。此外,DUSP 1也可能是其他纤维化肺病(例如进行性肺纤维化)的有效治疗靶点。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David W. Riches其他文献

David W. Riches的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David W. Riches', 18)}}的其他基金

Targeting early events in MUC5B-driven lung injury and fibrosis
针对 MUC5B 驱动的肺损伤和纤维化的早期事件
  • 批准号:
    10627600
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
Alveolar Septal Fibroblast Loss and The Pathogenesis of Emphysema
肺泡间隔成纤维细胞丢失与肺气肿的发病机制
  • 批准号:
    10609797
  • 财政年份:
    2017
  • 资助金额:
    $ 39.63万
  • 项目类别:
Alveolar Septal Fibroblast Loss and The Pathogenesis of Emphysema
肺泡间隔成纤维细胞丢失与肺气肿的发病机制
  • 批准号:
    10367957
  • 财政年份:
    2017
  • 资助金额:
    $ 39.63万
  • 项目类别:
Therapeutic Targeting of PTPN13 in Idiopathic Pulmonary Fibrosis
PTPN13 在特发性肺纤维化中的治疗靶向
  • 批准号:
    9142965
  • 财政年份:
    2017
  • 资助金额:
    $ 39.63万
  • 项目类别:
Aspen Lung Conference: Rebuilding the Injured Lung
阿斯彭肺会议:重建受伤的肺
  • 批准号:
    8711900
  • 财政年份:
    2014
  • 资助金额:
    $ 39.63万
  • 项目类别:
DUSP1 as a therapeutic target in fibroproliferative acute lung injury
DUSP1作为纤维增殖性急性肺损伤的治疗靶点
  • 批准号:
    8503966
  • 财政年份:
    2013
  • 资助金额:
    $ 39.63万
  • 项目类别:
Initial functional characterization of TRUSS-deficient mice
TRUSS 缺陷小鼠的初步功能表征
  • 批准号:
    8511974
  • 财政年份:
    2013
  • 资助金额:
    $ 39.63万
  • 项目类别:
Initial functional characterization of TRUSS-deficient mice
TRUSS 缺陷小鼠的初步功能表征
  • 批准号:
    8649023
  • 财政年份:
    2013
  • 资助金额:
    $ 39.63万
  • 项目类别:
DUSP1 as a therapeutic target in fibroproliferative acute lung injury
DUSP1作为纤维增殖性急性肺损伤的治疗靶点
  • 批准号:
    8665478
  • 财政年份:
    2013
  • 资助金额:
    $ 39.63万
  • 项目类别:
Lung specific TNF-R1 signaling in TRUSS null mice
TRUSS 无效小鼠的肺特异性 TNF-R1 信号传导
  • 批准号:
    7496933
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了